Philip Poortmans, co-author of a prestigious synthesis on breast cancer
It is an honor to be invited to participate in this project
said Professor Philip Poortmans.
It is of particular importance that the head of the Department of Radiation Therapy Oncology at Institut Curie is one of the most recognized international specialists in the domain of breast cancer, its treatment by radiotherapy and research in this field, and that the Institut, the cradle of radiotherapy, remains one of the major centers of this discipline.
Thirty-one pages is too much and too little at the same to document this pathology. This article took up "a lot of work, over three years", according to Professor Poortmans and his co-authors from the four corners of the world, from the United States to Australia and China, but with a strong European and especially French presence, with two authors: Prof. Poortmans, who practices at Institut Curie and Prof. Frédérique Penault-Llorca, pathologist in charge of the Center for the fight against cancer Jean-Perrin in Clermont-Ferrand. All of them were invited by Prof. Nadia Harbeck, a surgical gynecologist who heads the Department of Gynecology and Obstetrics at the University Hospital in Munich, Germany, and Prof. Fatima Cardoso, a medical oncologist who heads the senology unit at the Champalimaud Clinical Center/Champalimaud Foundation in Lisbon, Portugal, who Nature had chosen to lead this work.
Nature is one of the top-rated scientific journals," says Prof. Poortmans," and this press group has been enriched by several other titles in recent years that have quickly achieved exceptional Impact Factors (quality measurement index of a scientific publication, note)!
This is the case with the Nature Reviews Disease Primers magazine, which was launched in 2015 to bring together dense, synthetic articles that explore pathology and open-ended research questions. There is no shortage of them on the topic of breast cancer: the authors call in particular for the development of quality of life assessment tools for patients with metastatic cancers and for the study of the mechanisms of resistance of tumors to treatments.